Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $50,519.44 in Stock

Posted by Brenda Bartman on Sep 13th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) insider Dennis Cho sold 412 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44. Following the transaction, the insider directly owned 73,651 shares in the company, valued at approximately $9,031,085.62. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75.
On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The shares were sold at an average price of $87.32, for a total transaction of $30,212.72.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $127.22 on Friday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $155.44. The company’s 50 day moving average price is $113.51 and its two-hundred day moving average price is $79.33. The firm has a market cap of $7.98 billion, a PE ratio of -57.31 and a beta of 2.22. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 earnings per share. Equities research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of the business. California State Teachers Retirement System boosted its stake in Twist Bioscience by 10,945.7% in the second quarter. California State Teachers Retirement System now owns 7,770,424 shares of the company’s stock valued at $799,421,000 after buying an additional 7,700,076 shares in the last quarter. ARK Investment Management LLC raised its stake in Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after acquiring an additional 832,687 shares in the last quarter. William Blair Investment Management LLC raised its stake in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares in the last quarter. BlackRock Inc. bought a new position in shares of Twist Bioscience in the second quarter worth about $600,191,000. Finally, EdgePoint Investment Group Inc. lifted its holdings in shares of Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TWST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Piper Sandler raised their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, BWS Financial started coverage on shares of Twist Bioscience in a report on Wednesday. They issued a “sell” rating and a $45.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.45.

Check Out Our Latest Research Report on TWST

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.